TherapeuticsMD terminates employment agreement of CFO Michael Donegan; remains as consulting CFO

TherapeuticsMD, Inc.

CFO Michael Donegan's employment agreement terminated without 'Good Cause' effective Dec 30, 2022.
Separation benefits: 12-month base salary, 2022 target bonus, 24 months COBRA, full equity vesting.
Eligible for $135k in performance bonuses under 2022 ERB-Plan, including $67.5k for transition assistance.
Donegan continues as Principal Financial Officer and Principal Accounting Officer in consulting capacity.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Michael Donegan

Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance

TXMD · TherapeuticsMD, Inc.

Effective: 2022-12-30
Filed: January 18, 2023, 6:59 PM ET

Mr. Donegan is continuing to serve as the Company’s Principal Financial Officer and Principal Accounting Officer in a consulting capacity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Donegan was terminated as Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance at TherapeuticsMD, Inc..

Action: terminated
Role: Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance

Exact text from the filing

Mr. Donegan is continuing to serve as the Company’s Principal Financial Officer and Principal Accounting Officer in a consulting capacity.

View on SEC.gov

TherapeuticsMD, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-010258

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.